First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy
The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed…
Myeloma
Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma
Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an…
FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma.
First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo
The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex…
PT-112 Shows Promise for Heavily Treated Myeloma Patients
Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory…
MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials
The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK cell therapy into clinical trials…
FDA Approval Sought for Cilta-cel CAR T-cell Therapy
Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults…
FDA Approves Xpovio Triple Combo for Previously Treated Myeloma
The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment…
GSK Seeks Ideas for Improving Life in Myeloma Community
A new initiative by GlaxoSmithKline (GSK) is seeking project proposals that will address key needs for people in the multiple myeloma community. Submissions…
Bispecific Antibody Shows Early, Promising Responses in Trial
PF-06863135, a bispecific antibody being developed by Pfizer as an injectable treatment, shows a manageable safety profile and promising response rates at high dose…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL